3.4.17.23 (2S)-3-(biphenyl-4-yl)-2-((3S)-2-mercapto-3-methylpentanamido)propanoic acid - 65089 3.4.17.23 (2S)-3-biphenyl-4-yl-2-[(2-methyl-2-sulfanylpropanoyl)amino]propanoic acid - 65090 3.4.17.23 (2S)-3-biphenyl-4-yl-2-[(2-sulfanylpropanoyl)amino]propanoic acid - 65091 3.4.17.23 (2S)-3-biphenyl-4-yl-2-[(sulfanylacetyl)amino]propanoic acid - 65092 3.4.17.23 (2S)-3-biphenyl-4-yl-2-[[(2R)-2-sulfanylbutanoyl]amino]propanoic acid - 65093 3.4.17.23 (2S)-3-biphenyl-4-yl-2-[[(2R)-3-methyl-2-sulfanylbutanoyl]amino]propanoic acid - 65094 3.4.17.23 (2S)-3-biphenyl-4-yl-2-[[(2R)-3-phenyl-2-sulfanylpropanoyl]amino]propanoic acid - 65095 3.4.17.23 (2S)-3-biphenyl-4-yl-2-[[(2S)-2-phenyl-2-sulfanylacetyl]amino]propanoic acid - 65096 3.4.17.23 (2S)-3-biphenyl-4-yl-2-[[(2S)-2-sulfanylhexanoyl]amino]propanoic acid - 65097 3.4.17.23 (2S)-3-biphenyl-4-yl-2-[[(2S)-3-phenyl-2-sulfanylpropanoyl]amino]propanoic acid - 65098 3.4.17.23 (2S)-3-biphenyl-4-yl-2-[[cyclobutyl(sulfanyl)acetyl]amino]propanoic acid - 65099 3.4.17.23 (S)-3-(biphenyl-4-yl)-2-((2R,3R)-2-mercapto-3-methylpentanamido)propanoic acid - 65255 3.4.17.23 (S)-3-(biphenyl-4-yl)-2-((R)-2-cyclohexyl-2-mercaptoacetamido)propanoic acid - 65256 3.4.17.23 (S)-3-(biphenyl-4-yl)-2-((R)-2-cyclopentyl-2-mercaptoacetamido)propanoic acid - 65257 3.4.17.23 (S)-3-(biphenyl-4-yl)-2-((R)-2-mercapto-3-(naphthalen-2-yl)propanamido)propanoic acid - 65258 3.4.17.23 (S)-3-(biphenyl-4-yl)-2-((R)-2-mercapto-4,4-dimethylpentanamido)propanoic acid - 65259 3.4.17.23 (S)-3-(biphenyl-4-yl)-2-((R)-2-mercapto-4-methylpentanamido)propanoic acid - 65260 3.4.17.23 (S)-3-(biphenyl-4-yl)-2-((R)-2-mercapto-4-phenylbutanamido)propanoic acid - 65261 3.4.17.23 (S)-3-(biphenyl-4-yl)-2-((R)-3-cyclohexyl-2-mercaptopropanamido)propanoic acid - 65262 3.4.17.23 (S,S)-2-[1-carboxy-2-[3-(3,5-dichlorobenzyl)-3H-inidazol-4-yl]-ethylamino]-4-methylpentanoic acid MLN-4760 66693 3.4.17.23 (S,S)-2-{1-carboxy-2-[3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl]-ethylamino}-4-methylpentanoic acid i.e MLN-4760 147276 3.4.17.23 1,3,8-trihydroxy-6-methylanthraquinone 1,3,8-trihydroxy-6-methylanthraquinone (emodin) blocks interaction between the SARS corona virus spike protein and its receptor angiotensin-converting enzyme 2, 94.12% inhibition at 0.05 mM 37045 3.4.17.23 1,4-bis-(1-anthraquinonylamino)-anthraquinone slight inhibition 139213 3.4.17.23 1,8,dihydroxy-3-carboxyl-9,10-anthraquinone 1,8,dihydroxy-3-carboxyl-9,10-anthraquinone (rhein) exhibits slight inhibition 139212 3.4.17.23 10-hydroxyusambarensine binding energy -10.4 kcal/mol, and binding energy to SARS-CoV-2 spike protein is -9.4 kcal/mol 261011 3.4.17.23 1N-08795 90% inhibition at 0.2 mM 66665 3.4.17.23 1N-26923 93% inhibition at 0.2 mM 66668 3.4.17.23 1N-27714 89% inhibition at 0.2 mM 139201 3.4.17.23 1N-28616 93% inhibition at 0.2 mM 66667 3.4.17.23 1S-90995 11% inhibition at 0.2 mM 139209 3.4.17.23 1S-91206 75% inhibition at 0.2 mM 66666 3.4.17.23 2-benzyl-3-(hydroxy-pyrrolidin-2-yl-phosphinoyl)-propionic acid - 66679 3.4.17.23 2-benzyl-3-[(1-benzyloxycarbonylamino-2-phenyl-ethyl)-hydroxy-phosphinoyl]-propionic acid - 66674 3.4.17.23 2-benzyl-3-[(1-benzyloxycarbonylamino-3-methyl-butyl)-hydroxy-phosphinoyl]-propionic acid - 66675 3.4.17.23 2-benzyl-3-[(1-benzyloxycarbonylamino-ethyl)-hydroxy-phosphinoyl]-propionic acid - 66673 3.4.17.23 2-methylphenyl-benzylsuccinic acid - 125187 3.4.17.23 2-[(2-carboxy-3-phenyl-propyl)-hydroxy-phosphinoyl]-pyrrolidine-1-carboxylic acid benzyl ester - 66670 3.4.17.23 2-[(2-carboxy-4-methyl-pentyl)-hydroxy-phosphinoyl]-pyrrolidine-1-carboxylic acid benzyl ester - 66671 3.4.17.23 2-[(2-carboxy-propyl)-hydroxy-phosphinoyl]-pyrrolidine-1-carboxylic acid benzyl ester - 66672 3.4.17.23 3,4-dimethylphenyl-benzylsuccinic acid - 125184 3.4.17.23 3,5-dichloro-benzylsuccinate - 125183 3.4.17.23 3,5-dimethylphenyl-benzylsuccinic acid - 125185 3.4.17.23 3-([1-[2-acetylamino-3-(1H-imidazol-4-yl)-propionylamino]-3-methyl-butyl]-hydroxy-phosphinoyl)-2-(3-phenyl-isoxazol-5-ylmethyl)-propionic acid - 66692 3.4.17.23 3-([1-[2-acetylamino-3-(1H-imidazol-4-yl)-propionylamino]-3-methyl-butyl]-hydroxy-phosphinoyl)-2-benzyl-propionic acid - 66689 3.4.17.23 3-([1-[2-acetylamino-3-(1H-imidazol-4-yl)-propionyl]-pyrrolidin-2-yl]-hydroxy-phosphinoyl)-2-(3-phenyl-isoxazol-5-ylmethyl)-propionic acid - 66691 3.4.17.23 3-([1-[2-acetylamino-3-(1H-imidazol-4-yl)-propionyl]-pyrrolidin-2-yl]-hydroxy-phosphinoyl)-2-benzyl-propionic acid - 66687 3.4.17.23 3-([1-[2-acetylamino-3-(4-hydroxy-phenyl)-propionyl]-pyrrolidin-2-yl]-hydroxy-phosphinoyl)-2-benzyl-propionic acid - 66684 3.4.17.23 3-methylphenyl-benzylsuccinic acid - 125186 3.4.17.23 3-[(1-amino-2-phenyl-ethyl)-hydroxy-phosphinoyl]-2-benzylpropionic acid - 66677 3.4.17.23 3-[(1-amino-3-methyl-butyl)-hydroxy-phosphinoyl]-2-benzylpropionic acid - 66678 3.4.17.23 3-[(1-amino-ethyl)-hydroxy-phosphinoyl]-2-benzyl-propionic acid - 66676 3.4.17.23 3-[[1-(2-acetylamino-3-methyl-butyryl)-pyrrolidin-2-yl]-hydroxy-phosphinoyl]-2-benzyl-propionic acid - 66681 3.4.17.23 3-[[1-(2-acetylamino-3-phenyl-propionyl)-pyrrolidin-2-yl]-hydroxy-phosphinoyl]-2-benzyl-propionic acid - 66685 3.4.17.23 3-[[1-(2-acetylamino-4-methyl-pentanoyl)-pyrrolidin-2-yl]-hydroxy-phosphinoyl]-2-(3-phenyl-isoxazol-5-ylmethyl)-propionic acid - 66690 3.4.17.23 3-[[1-(2-acetylamino-4-methyl-pentanoyl)-pyrrolidin-2-yl]-hydroxy-phosphinoyl]-2-benzyl-propionic acid - 66686 3.4.17.23 3-[[1-(2-acetylamino-4-methyl-pentanoylamino)-2-phenylethyl]-hydroxy-phosphinoyl]-2-benzyl-propionic acid - 66688 3.4.17.23 3-[[1-(2-acetylamino-6-amino-hexanoyl)-pyrrolidin-2-yl]-hydroxy-phosphinoyl]-2-benzyl-propionic acid - 66682 3.4.17.23 3-[[1-(2-acetylamino-propionyl)-pyrrolidin-2-yl]-hydroxyphosphinoyl]-2-benzyl-propionic acid - 66680 3.4.17.23 3S-95223 40% inhibition at 0.2 mM 139203 3.4.17.23 4-acetylamino-5-[2-[(2-carboxy-3-phenyl-propyl)-hydroxyphosphinoyl]-pyrrolidin-1-yl]-5-oxo-pentanoic acid - 66683 3.4.17.23 4-methylphenyl-benzylsuccinic acid - 125188 3.4.17.23 4-nitrophenyl-benzylsuccinic acid - 125189 3.4.17.23 4S-14713 70% inhibition at 0.2 mM 66669 3.4.17.23 4S-16659 76% inhibition at 0.2 mM 66664 3.4.17.23 5,7-dihydroxyflavone 5,7-dihydroxyflavone (chrysin) is a weak inhibitor 3522 3.4.17.23 5115980 1% inhibition at 0.2 mM 139211 3.4.17.23 6-gingerol inhibition of the ACE2 enzyme 210595 3.4.17.23 7490938 20% inhibition at 0.2 mM 139205 3.4.17.23 7850455 20% inhibition at 0.2 mM 139206 3.4.17.23 7857351 27% inhibition at 0.2 mM 139204 3.4.17.23 7870029 11% inhibition at 0.2 mM 139208 3.4.17.23 Ac-GDYSHCSPLRYYPWWKCTYPDPEGGG-NH2 strong inhibition, most potent inhibitory peptide, i.e. DX600 57056 3.4.17.23 Ac-GDYSHCSPLRYYPWWPDPEGGG-NH2 i.e. DX600 159783 3.4.17.23 amentoflvaone inhibitor of SARS-CoV-2-(receptor binding domain):ACE2 complex 259911 3.4.17.23 Amphotericin B binding affinity -10.50 kcal/mol, favorable binding modes, critical interactions, and pharmaceutical properties 5518 3.4.17.23 andrographolide inhibition of the ACE2 enzyme 160256 3.4.17.23 angiotensin I - 690 3.4.17.23 angiotensin II C-terminal analogs screening of a library of angiotensin II C-terminal analogs identifies a number of tetrapeptides with increased ACE2 inhibition, and identifies residues critical to the binding of angiotensin II to the active site of ACE2 151505 3.4.17.23 anthraquinone slight inhibition 16780 3.4.17.23 apigenin inhibition of the ACE2 enzyme 515 3.4.17.23 arbidol inhibitor of SARS-CoV-2-(receptor binding domain):ACE2 complex 259914 3.4.17.23 artemisnin inhibition of the ACE2 enzyme 259897 3.4.17.23 asparoside C inhibitor of SARS-CoV-2-(receptor binding domain):ACE2 complex 259906 3.4.17.23 AY-NH2 inhibitor of SARS-CoV-2-(receptor binding domain):ACE2 complex 259909 3.4.17.23 benzyl (6aS,9aS)-10-benzyl-4-[benzyl(methyl)amino]-8-(cyclopropanecarbonyl)-6a,7,8,9,9a,10-hexahydrocyclopenta[b]pyrimido[4,5-e][1,4]diazepine-6(5H)-carboxylate inhibits the protein-protein interaction between ACE2 and the receptor-binding domain of SARS-CoV-2 spike protein and suppresses SARS-CoV-2 infection in cultured cells by inhibiting viral entry via the modulation of ACE2. The compound does not have any adverse effect on ACE2 function 261806 3.4.17.23 benzyl (6aS,9aS)-4-[benzyl(methyl)amino]-10-[(4-chlorophenyl)methyl]-8-(cyclopropanecarbonyl)-6a,7,8,9,9a,10-hexahydrocyclopenta[b]pyrimido[4,5-e][1,4]diazepine-6(5H)-carboxylate inhibits the protein-protein interaction between ACE2 and the receptor-binding domain of SARS-CoV-2 spike protein and suppresses SARS-CoV-2 infection in cultured cells by inhibiting viral entry via the modulation of ACE2. The compound does not have any adverse effect on ACE2 function 261807 3.4.17.23 benzyl (6aS,9aS)-4-[benzyl(methyl)amino]-8-(cyclopropanecarbonyl)-10-[(4-methylphenyl)methyl]-6a,7,8,9,9a,10-hexahydrocyclopenta[b]pyrimido[4,5-e][1,4]diazepine-6(5H)-carboxylate inhibits the protein-protein interaction between ACE2 and the receptor-binding domain of SARS-CoV-2 spike protein and suppresses SARS-CoV-2 infection in cultured cells by inhibiting viral entry via the modulation of ACE2. The compound does not have any adverse effect on ACE2 function 261808 3.4.17.23 benzylsuccinate essentially abolishes the formation of Ang(1-9) by ACE2 16344 3.4.17.23 Benzylsuccinic acid - 10600 3.4.17.23 Berberine inhibition of the ACE2 enzyme 1612 3.4.17.23 beta-sitosterol inhibition of the ACE2 enzyme 3989 3.4.17.23 bis-demethoxy curcumin inhibitor of SARS-CoV-2-(receptor binding domain):ACE2 complex 163590 3.4.17.23 cepharanthine potential inhibitor of the SARS-CoV-2-S protein:ACE2 complex 49936 3.4.17.23 chebulagic acid inhibitor of SARS-CoV-2-(receptor binding domain):ACE2 complex 259913 3.4.17.23 chrysin shows a strong affinity for the active site of ACE2, ACE2-inhibitor complexes display structural stability with suitable binding energies. The interaction of chrysin with Phe40, Asp350, and Gly352 on ACE2 can interfere with the binding of SARS-CoV-2 1727 3.4.17.23 Cl- inhibition is substrate dependent, inhibitory with substrate angiotensin II 141 3.4.17.23 Cl- ACE2 activity is regulated by chloride ions. The presence of chloride increases the hydrolysis of angiotensin I by ACE2, but inhibits cleavage of the vasoconstrictor angiotensin II 141 3.4.17.23 crisimaritin inhibition of the ACE2 enzyme 259898 3.4.17.23 cryptoquindoline binding energy -9.9 kcal/mol, and binding energy to SARS-CoV-2 spike protein is -9.5 kcal/mol 261827 3.4.17.23 cryptospirolepine binding energy -10.7 kcal/mol, and binding energy to SARS-CoV-2 spike protein is -10.6 kcal/mol 261828 3.4.17.23 Cu2+ 69% inhibition at 0.01 mM 19 3.4.17.23 cucurbitacin B inhibition of the ACE2 enzyme 48929 3.4.17.23 curcumin inhibition of the ACE2 enzyme 696 3.4.17.23 cyclohexyl-benzylsuccinic acid - 125191 3.4.17.23 cynaropicrin inhibition of the ACE2 enzyme 15319 3.4.17.23 darunavir inhibitor of SARS-CoV-2-(receptor binding domain):ACE2 complex 1901 3.4.17.23 denopamine inhibitor of SARS-CoV-2-(receptor binding domain):ACE2 complex 7525 3.4.17.23 dicyclohexyl-benzylsuccinic acid - 125190 3.4.17.23 digitoxin binding affinity -11.25 kcal/mol, favorable binding modes, critical interactions, and pharmaceutical properties 13679 3.4.17.23 dithymoquinone inhibitor of SARS-CoV-2-(receptor binding domain):ACE2 complex 259912 3.4.17.23 DRVYIYbetaPF angiotensin II chimera prepared by combining key elements of ACE2 binding and proteolytic stability, 90% inhibition at 10 microM and complete resistance to cleavage over 5 h 239480 3.4.17.23 DRVYIYPF angiotensin II chimera prepared by combining key elements of ACE2 binding and proteolytic stability, 96% inhibition at 10 microM and 18% cleavage over 5h 239479 3.4.17.23 DX600 IC50: 10 nM 5806 3.4.17.23 DX600 competitive inhibitor, 0.1 mM 5806 3.4.17.23 DX600 - 5806 3.4.17.23 DX600 0.01 mM, 99% inhibition 5806 3.4.17.23 DX600 a decrease in thrombus ACE2 activity is associated with increased thrombus formation in nude mice 5806 3.4.17.23 DX600 a decrease in thrombus ACE2 activity is associated with increased thrombus formation in spontaneously hypertensive rats 5806 3.4.17.23 EDTA no inhibition by benzylsuccinate, no inhibition by lisinopril, no inhibition by captopril, no inhibition by enalaprilat 21 3.4.17.23 EDTA complete inhibition at 10 mM 21 3.4.17.23 ergoloid potential inhibitor of the SARS-CoV-2-S protein:ACE2 complex 259902 3.4.17.23 eriodictyol potential inhibitor of the SARS-CoV-2-S protein:ACE2 complex 2485 3.4.17.23 Evans blue inhibits viral replication in a Vero-E6 cell-based SARS-CoV-2 infection assay 49046 3.4.17.23 favipiravir potential inhibitor of the SARS-CoV-2-S protein:ACE2 complex 253227 3.4.17.23 glycyrrhizinate binding affinity -11.75 kcal/mol, favorable binding modes, critical interactions, and pharmaceutical properties 179224 3.4.17.23 hesperidin inhibition of the ACE2 enzyme; inhibitor of SARS-CoV-2-(receptor binding domain):ACE2 complex 2513 3.4.17.23 hispudulin inhibition of the ACE2 enzyme 259899 3.4.17.23 hydroxychloroquine docks at the active site of the Human ACE2 receptor as a possible way of inhibition; malaria drug hydroxychloroquine docks at the active site of the human ACE2 receptor as a possible way of inhibition, with a docking score and glide energy of -6.34 and -49.34 kcal/mol, respectively. Hydroxychloroquine forms two hydrogen bond interactions with active site amino acids of Asp367 and Asn277 at distances of 2.65 A and 2.85 A, respectively. In addition, pi-pi interactions are also observed from the active site of His345, and ionic interactions are found with Lys363 38397 3.4.17.23 hydroxychloroquine potential inhibitor of the SARS-CoV-2-S protein:ACE2 complex 38397 3.4.17.23 hypericin potential inhibitor of the SARS-CoV-2-S protein:ACE2 complex 2519 3.4.17.23 Ile-Pro-Pro inhibits EC 3.4.15.1 at one-thousandth of the concentration needed to inhibit ACE2 16366 3.4.17.23 isocryptolepine binding energy to SARS-CoV-2 spike protein is -9.7 kcal/mol 261883 3.4.17.23 isoniazid pyruvate potential inhibitor of the SARS-CoV-2-S protein:ACE2 complex 259903 3.4.17.23 isothymol inhibition of the ACE2 enzyme 259900 3.4.17.23 ivermectin inhibition of the ACE2 enzyme; potential inhibitor of the SARS-CoV-2-S protein:ACE2 complex 213760 3.4.17.23 ivermectin binding affinity -10.87 kcal/mol, favorable binding modes, critical interactions, and pharmaceutical properties 213760 3.4.17.23 Leu-Pro-Pro inhibits EC 3.4.15.1 at one-thousandth of the concentration needed to inhibit ACE2 31529 3.4.17.23 lumacaftor inhibits viral replication in a Vero-E6 cell-based SARS-CoV-2 infection assay 259916 3.4.17.23 luteolin shows a strong affinity for the active site of ACE2, ACE2-inhibitor complexes display structural stability with suitable binding energies 436 3.4.17.23 menthol potential inhibitor of the SARS-CoV-2-S protein:ACE2 complex 16818 3.4.17.23 methylene blue binding energy -4.89 kcal/mol, KD value 0.621mM 512 3.4.17.23 MLN 4760 IC50: 3 nM 24113 3.4.17.23 MLN-4760 i.e. (SS) 2-[(1)-carboxy-2-[3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl]ethylamino]-4-methyl-pentanoic acid, IC50: 0.44 nM 6262 3.4.17.23 MLN-4760 0.001 mM 6262 3.4.17.23 MLN-4760 specific inhibitor, 1 mM 6262 3.4.17.23 MLN-4760 0.01 mM 6262 3.4.17.23 MLN-4760 total inhibition at 0.01 mM 6262 3.4.17.23 MLN-4760 0.0001 mM 6262 3.4.17.23 MLN-4760 - 6262 3.4.17.23 MLN-4760 ACE2-specific inhibitor. Inhibition of wild-type ACE2 was sensitive to chloride concentration 6262 3.4.17.23 MLN-4760 i.e. ((S,S)-2-[1-carboxy-2-[3-(3,5-dichlorobenzyl)-3H-imidazol4-yl]-ethylamino]-4-methylpentanoic acid) 6262 3.4.17.23 MLN-4760 inhibitor of SARS-CoV-2-(receptor binding domain):ACE2 complex 6262 3.4.17.23 MLN-4760 binding energy -7.0 kcal/mol 6262 3.4.17.23 MLN4760 - 132649 3.4.17.23 additional information no inhibition by lisinopril 2 3.4.17.23 additional information no inhibition by captopril 2 3.4.17.23 additional information no inhibition by enalaprilat 2 3.4.17.23 additional information rampiril does not influence the mRNA content in renal tubules 2 3.4.17.23 additional information no inhibition by lisinopril, no inhibition by captopril, no inhibition by enalaprilat 2 3.4.17.23 additional information construction of 6 constrained peptide libraries, selected from peptide libraries displayed on phage, peptides, 21-27 amino acids, with inhibitory effects on the enzyme, specificity and stability, selection of inhibitory sequence motifs, best CXPXRXXPWXXC, overview 2 3.4.17.23 additional information carboxylalkyl compounds cilazaprilat, indolaprilat, perindoprilat, quinaprilat and spiraprilat, the thiol compounds rentiapril and zofenapril, and the phosphoryl compounds ceranopril and fosinoprilat fail to inhibit the hydrolysis of either angiotensin I or angiotensin II by ACE2 at concentrations that abolished activity of EC 3.4.15.1 2 3.4.17.23 additional information ACE-2 mRNA and activity are severely downregulated in lung fibrosis 2 3.4.17.23 additional information not inhibited by captopri and lisinopril 2 3.4.17.23 additional information the Spike protein of the SARS-coronavirus reduces ACE2 expression 2 3.4.17.23 additional information not inhibited by captopril and benzyloxycarbonyl-Pro-Pro 2 3.4.17.23 additional information not inhibited by Ca2+, Cd2+, Co2+, Mg2+, Mn2+, and Zn2+ 2 3.4.17.23 additional information GM6001 does not have any effect on the activity of ACE2 and little effect on basal shedding of ACE2 2 3.4.17.23 additional information not inhibited by rentiapril, ceranopril, indolaprilat, zofenoprilat, spiraprilat, quinaprilat, perindoprilat, fosinoprilat, cilazaprilat, captopril, lisinopril, and enalaprilat 2 3.4.17.23 additional information ACE2 is insensitive to ACE inhibitors 2 3.4.17.23 additional information central angiotensin II type 1 receptors reduce ACE2 expression/activity in hypertensive mice 2 3.4.17.23 additional information chronic cigarette smoke administration causes an reduction in ACE2 activity and increases angiotensin II levels in the lung 2 3.4.17.23 additional information identification of compounds that bind to either the angiotensin converting enzyme 2 (ACE2) and/or the SARS-CoV-2 spike protein receptor binding domain (SARS-CoV-2 spike protein RBD). All 22 identified compounds provide scaffolds for the development of new chemical entities for the treatment of COVID-19 2 3.4.17.23 additional information inhibitors of SARS-CoV-2:ACE2 binding 2 3.4.17.23 additional information ACE2 activity is not regulated by ibuprofen, flurbiprofen, etoricoxib or paracetamol 2 3.4.17.23 additional information ACE2 activity in plasma is not altered by ibuprofen treatment 2 3.4.17.23 N-acetyl-D-glucosamine binding energy -5.6 kcal/mol 300 3.4.17.23 N-[(1S)-1-carboxy-3-methylbutyl]-3-(3,5-dichlorobenzyl)-L-histidine enzyme-specific inhibitor 125182 3.4.17.23 N-[(1S)-1-carboxy-3-methylbutyl]-3-(3,5-dichlorophenyl)-L-histidine i.e. C16, a ACE2 specific inhibitor 138131 3.4.17.23 naringin inhibition of the ACE2 enzyme 2858 3.4.17.23 neoandrographolide inhibitor of SARS-CoV-2-(receptor binding domain):ACE2 complex 117934 3.4.17.23 Nitrofurantoin potential inhibitor of the SARS-CoV-2-S protein:ACE2 complex 2494 3.4.17.23 orientin inhibition of the ACE2 enzyme 232573 3.4.17.23 paritaprevir inhibition of the ACE2 enzyme 237045 3.4.17.23 phenylbenzylsuccinic acid - 125192 3.4.17.23 PHVF angiotensin II analog, shows almost saturating levels of inhibition at the screening concentration of 100 microm 239477 3.4.17.23 piceatannol inhibitor of SARS-CoV-2-(receptor binding domain):ACE2 complex 6176 3.4.17.23 pimozide effectively binds to the ACE2 binding site for SARS-CoV-2 spike protein, does not show stability during molecular dynamics simulation 72164 3.4.17.23 Pro-Phe IC50: 0.15 mM 6641 3.4.17.23 Pro-Phe - 6641 3.4.17.23 pseudojervine inhibitor of SARS-CoV-2-(receptor binding domain):ACE2 complex 259905 3.4.17.23 PYPF angiotensin II analog, shows almost saturating levels of inhibition at the screening concentration of 100 microm 239476 3.4.17.23 PYVF angiotensin II analog, shows almost saturating levels of inhibition at the screening concentration of 100 microm 239478 3.4.17.23 quercetin inhibition of the ACE2 enzyme 137 3.4.17.23 quercetin KD value 0.130 mM 137 3.4.17.23 quercetin-3-O-galatosyl-rhamnosyl-glucoside inhibitor of SARS-CoV-2-(receptor binding domain):ACE2 complex 259907 3.4.17.23 Quinacrine KD value 0.102 mM 1593 3.4.17.23 Rapamycin binding affinity -10.57 kcal/mol, favorable binding modes, critical interactions, and pharmaceutical properties 4862 3.4.17.23 raspberry ketone potential inhibitor of the SARS-CoV-2-S protein:ACE2 complex 259904 3.4.17.23 rifaximin binding affinity -10.54 kcal/mol, favorable binding modes, critical interactions, and pharmaceutical properties 262527 3.4.17.23 rutin inhibition of the ACE2 enzyme 1095 3.4.17.23 rutin DAB10 inhibitor of SARS-CoV-2-(receptor binding domain):ACE2 complex 259908 3.4.17.23 saikosaponin A inhibition of the ACE2 enzyme 162299 3.4.17.23 sennoside A binding energy -4.51 kcal/mol, KD value 0.041 mM 28099 3.4.17.23 sodium lifitegrast inhibits viral replication in a Vero-E6 cell-based SARS-CoV-2 infection assay 259915 3.4.17.23 spinochrome A inhibitor of SARS-CoV-2-(receptor binding domain):ACE2 complex 259910 3.4.17.23 strychnopentamine binding energy -9.9 kcal/mol 262142 3.4.17.23 sunitinib KD value 0.781 mM 25420 3.4.17.23 T0507-4963 41% inhibition at 0.2 mM 139202 3.4.17.23 T0513-5544 4% inhibition at 0.2 mM 139210 3.4.17.23 T0515-3007 13% inhibition at 0.2 mM 139207 3.4.17.23 telmisartan specific angiotensin II type 1 receptor blocker 6286 3.4.17.23 thymoquinone potential inhibitor of the SARS-CoV-2-S protein:ACE2 complex 18394 3.4.17.23 Ursodeoxycholic acid effectively binds to the ACE2 binding site for SARS-CoV-2 spike protein, does not show stability during molecular dynamics simulation 4288 3.4.17.23 Val-Pro-Pro inhibits EC 3.4.15.1 at one-thousandth of the concentration needed to inhibit ACE2 17102 3.4.17.23 varenicline binding energy -4.42 kcal/mol, KD value 0.017 mM 262528 3.4.17.23 vitexin inhibition of the ACE2 enzyme 9294 3.4.17.23 Z-prolyl-prolinal - 201564